DGAP-News: Synergy Pharmaceuticals Achieves Halfway Mark in Enrollment on Plecanatide Phase II/III Trial in Chronic Idiopathic Constipation
Synergy Pharmaceuticals
09.04.2012 13:15
—————————————————————————
NEW YORK, 2012-04-09 13:15 CEST (GLOBE NEWSWIRE) —
Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) (Nasdaq:SGYPU) (Nasdaq:SGYPW), a
developer of new drugs to treat gastrointestinal disorders and diseases, today
announced that it has successfully achieved the halfway mark for total
enrollment in its ongoing plecanatide Phase II/III clinical trial in chronic
idiopathic constipation
